Molina Healthcare Shares Slide as Forecast Weighs on Results

Key Moments

Revenue Outlook Weighs on Stock Despite EPS Beat

Molina Healthcare stock is falling 9.2% in pre-open trading after the managed care company released its second-quarter 2026 results following Wednesday’s close. The company topped profit expectations but unsettled investors with a full-year revenue forecast that is notably below Wall Street projections.

For the quarter, Molina reported adjusted earnings per share of $1.51, ahead of analyst expectations of approximately $1.39–$1.40. Revenue came in at roughly $10.87 billion, which was essentially in line with market forecasts. However, the company reaffirmed its full-year 2026 revenue outlook at approximately $42 billion, well under the analyst consensus of around $44.28 billion.

Guidance Shift Highlights Margin and Enrollment Pressures

On the earnings outlook, Molina raised its full-year adjusted EPS guidance floor to at least $5.25, up from a prior minimum of $5.00. That improvement in profit expectations has not been enough to offset market concern about the sizable revenue gap, continued pressure on Marketplace enrollment, and startup expenses related to the Florida CMS Medicaid contract.

Membership continued to move lower during the quarter. Molina ended the period serving approximately 4.9 million members, a decline from 5.0 million at the end of the first quarter.

The company’s earnings call, scheduled for the morning of July 23, has added to the caution in pre-market trading as investors react to CEO Joseph Zubretsky’s description of 2026 as the “trough year” for Medicaid pretax margins.

Market Context and Analyst Positioning

The broader equity market is also softer in today’s session, providing little support for the stock. The S&P 500 is down 0.3%, the Dow Jones is lower by 0.3%, and the Nasdaq is off 0.4%.

Analyst sentiment heading into the results had been mixed. Several firms, including TD Cowen and Truist, lifted their price targets meaningfully in mid-July. At the same time, Barclays cut its target to $184 from $199 earlier in the month, reflecting a more cautious stance on the managed care space amid ongoing medical cost pressures and contraction in Medicaid enrollment.

Pre-Market Trading Levels and Recent Stock Performance

The combination of a stronger bottom line, weaker top-line guidance, Medicaid cycle headwinds, and a subdued macro backdrop has reversed some of Molina’s recent gains. A market that had driven the stock sharply higher in the weeks before earnings is now refocusing on the company’s ability to stabilize or grow revenue.

In pre-market trading, Molina shares are changing hands at $201.27, placing the stock near the lower end of its 52-week range relative to its recent recovery high.

Key Figures at a Glance